U.S. stock market update: Werewolf Therapeutics up 10.34%

U.S. Stock Market Midday Update Stocks with High Trading Volume in the Industry uniQure rose 234.19%, with a trading volume of $2.607 billion. According to recent key news: On September 24, uniQure announced that its experimental gene therapy AMT-130 significantly slowed the progression of a brain disease in early to mid-stage studies. The disease progression was slowed by 75% in patients receiving high doses, which drove the stock price sharply higher. Data source: Reuters. On September 24, uniQure reached a $175 million non-dilutive senior secured term loan agreement with Hercules Capital. This move enhances the company's financial flexibility and reduces capital costs in preparation for the potential commercialization of AMT-130. Data source: Benzinga Pro. On September 23, analysts rated uniQure as a strong buy, with a target price of $39.33, representing an upside potential of 182.95% from current levels. This optimistic analyst expectation further propelled the stock price upward. Data source: TipRanks. The gene therapy industry is performing strongly, with significant capital inflows. AbbVie fell 1.64%, with a trading volume of $390 million. According to recent key news: On September 23, AbbVie announced that its injectable drug Acalbrutinib has applied for new indications in China, which may bring new market opportunities, but the market reacted poorly in the short term, leading to a decline in stock price. On September 23, AbbVie announced it would acquire Capstan for $2.1 billion, aiming to advance its immunology portfolio, but the market expressed concerns over acquisition costs and integration risks, putting pressure on the stock price. On September 25, a U.S. federal judge dismissed AbbVie and Novartis's challenge to block Maine's 340B drug discount program, increasing the company's legal and regulatory uncertainties, affecting investor confidence. The pharmaceutical industry is performing steadily overall, with active capital flows. Amgen fell 2.82%, with increased trading volume. According to recent key news: On September 24, analysts rated Amgen as "hold," believing that five other stocks are more attractive. This news may lead to a decline in investor confidence, putting pressure on the stock price. Data source: MarketBeat. On September 22, the market expressed concerns over the policy actions of the U.S. Secretary of Health and Human Services, which may have short-term impacts on the pharmaceutical industry, affecting Amgen's stock price. Data source: MarketBeat. On September 22, Amgen raised its 2025 non-GAAP earnings per share guidance, but this positive news failed to offset market concerns about overall industry pressures. Data source: Amgen. The pharmaceutical industry is facing policy pressures. Stocks with High Market Capitalization in the Industry Gilead Sciences fell 1.39%. According to recent key news: On September 24, Fosun Pharma's subsidiary Fosun Kite filed for the listing of Brexucabtagene Autoleucel injection, indicated for adult patients with relapsed/refractory precursor B-cell acute lymphoblastic leukemia. This news may impact Gilead Sciences' market performance, as the drug was developed by Gilead's Kite Pharma. On September 22, Ensoma announced it had secured $53 million in financing to support key clinical milestones for EN-374 and the ongoing development of its in vivo hematopoietic stem cell engineering pipeline. Gilead Sciences, as one of the investors, may influence its stock price. On September 24, Gilead Sciences partnered with the Global Fund to provide its branded drugs to 2 million people at reduced prices while increasing the production of generics. Long-term demand is expected to approach 10 million people, highlighting the necessity for large-scale production of affordable generics. The industry is highly competitive, and the capital environment is tightening